Portugal declines to reimburse liraglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
The Ledger
Page 10 of 25 of this archive, newest first.
Page 10
The named comparison we promised two years ago
The Journal submitted split samples from single lots to three assay services, under names unconnected to this publication, and published each method alongside each result.
South Korea caps liraglutide prescribing to 6 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Custody, condition and the temperature nobody logged
The condition on arrival is recorded by some services and not others, and it is one of the more informative lines in a report.
Norway declines to reimburse dulaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
STEP 2 was built to answer the stopping question, and it did
A withdrawal trial answers a narrower question than it appears to. This piece states which question.
Ireland declines to reimburse liraglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Ireland caps dulaglutide prescribing to 17 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
What a laboratory knows about the material it receives
A result on one vial generalises to a batch only if the vial was drawn in a way that makes it representative — and nobody records how it was drawn.
Denmark caps exenatide prescribing to 17 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Nigeria declines to reimburse dulaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
The dose that got you here and the dose that keeps you here
Every withdrawal trial compared full dose against nothing. The clinically interesting comparison — full dose against a reduced one — has not been randomised.
Brazil caps tirzepatide prescribing to 15 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
The Netherlands declines to reimburse semaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Argentina caps exenatide prescribing to 8 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Maintenance dosing: what is licensed, what is practised, and what is evidenced
Dose reduction is not withdrawal, and the trials that tested withdrawal cannot be read as testing it.
Two-thirds back: the extension nobody expected to be the headline
The evidence on stopping is better than the evidence on almost anything else in this field, because somebody deliberately randomised it.
Germany declines to reimburse liraglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
How a claim degrades between the bench and the listing
Every step between the laboratory report and the product page removes information, and the badge is the last step.
Japan declines to reimburse semaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.